This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2025 Feb;84(2):373.

doi: 10.1136/ard-2023-225473corr1.

Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

No authors listed

PMID: 39919910
DOI: 10.1136/ard-2023-225473corr1

Published Erratum

Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

No authors listed. Ann Rheum Dis. 2025 Feb.

. 2025 Feb;84(2):373.

doi: 10.1136/ard-2023-225473corr1.

PMID: 39919910
DOI: 10.1136/ard-2023-225473corr1

No abstract available

PubMed Disclaimer

Erratum for

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Feist E, Fleischmann RM, Fatenejad S, Bukhanova D, Grishin S, Kuzkina S, Luggen M, Nasonov E, Samsonov M, Smolen JS. Feist E, et al. Ann Rheum Dis. 2024 Oct 21;83(11):1454-1464. doi: 10.1136/ard-2023-225473. Ann Rheum Dis. 2024. PMID: 38955475 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science